$732 $778 $789 $802 $818 Optimal Operating Reserve Level Alternative 1: Proposed Fee Schedule – Setting and Adjusting Patent Fees during $2,951 $3,260 $3,265 $3,412 $3,599 Fiscal Year 2017 Aggregate Patent – Revenue $349 $513 $639 $861 $1,206 EOY Operating Reserve Alternative 1: Alternative 2: Unit Cost Recovery $2,971 $3,210 $3,277 $3,432 $3,599 – Aggregate Patent Revenue $369 $483 $621 $863 $1,208 EOY Operating Reserve Alternative 2: Alternative 3: Across the Board $2,947 $3,267 $3,267 $3,414 $3,602 Adjustment to Patent Fees Aggregate – Patent Revenue $345 $516 $644 $868 $1,216 EOY Operating Reserve Alternative 3: $2,878 $3,110 $3,110 $3,250 $3,429 Alternative 4: Baseline Aggregate Patent – Revenue $277 $292 $264 $325 $501 EOY Operating Reserve Alternative 4: Over the five-year timeframe of this analysis (FY 2017 FY 2021), the Office projects that – Alternatives 1, 2, and 3 secure a sufficient amount of aggregate revenue to sustain progress on the Office’s core mission programs and strategic initiatives. The Baseline does not generate enough revenue to achieve the operating reserve minimum balance of $300 million until the end of FY 2020 and does not achieve the optimal three month patent operating reserve during the five year horizon. Section 4 provides detailed discussions of each alternative.
Optimal Operating Reserve Level $732 $778 $789 $802 $818 Alternative 1: Proposed Fee Schedule – Setting and Adjusting Patent Fees during Fiscal Year 2017 – Aggregate Patent Revenue $2,951 $3,260 $3,265 $3,412 $3,599 EOY Operating Reserve Alternative 1: $349 $513 $639 $861 $1,206 Alternative 2: Unit Cost Recovery – Aggregate Patent Revenue $2,971 $3,210 $3,277 $3,432 $3,599 EOY Operating Reserve Alternative 2: $369 $483 $621 $863 $1,208 Alternative 3: Across the Board Adjustment to Patent Fees – Aggregate Patent Revenue $2,947 $3,267 $3,267 $3,414 $3,602 EOY Operating Reserve Alternative 3: $345 $516 $644 $868 $1,216 Alternative 4: Baseline – Aggregate Patent Revenue $2,878 $3,110 $3,110 $3,250 $3,429 EOY Operating Reserve Alternative 4: $277 $292 $264 $325 $501 Over the five-year timeframe of this analysis (FY 2017 – FY 2021), the Office projects that Alternatives 1, 2, and 3 secure a sufficient amount of aggregate revenue to sustain progress on the Office’s core mission programs and strategic initiatives. The Baseline does not generate enough revenue to achieve the operating reserve minimum balance of $300 million until the end of FY 2020 and does not achieve the optimal three month patent operating reserve during the five year horizon. Section 4 provides detailed discussions of each alternative.
Regulatory%20Impact%20Analysis.docx